Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis

Published:2017-09-04 Issue:11 Volume:37 Page:1009-1023
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Ahmed Hussien,Abushouk Abdelrahman Ibrahim,Menshawy Amr,Mohamed Arwa,Negida Ahmed,Loutfy Samah A.,Abdel-Daim Mohamed M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-017-0565-5/fulltext.html

Reference39 articles.

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. doi: 10.1002/hep.26141 .

2. Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76. doi: 10.1016/S2468-1253(16)30181-9 .

3. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21, 521.e1–6. doi: 10.1053/j.gastro.2009.09.067 .

4. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis. 2008;12:661–74. doi: 10.1016/j.cld.2008.03.007 .

5. Lee M-H, Yang H-I, Yuan Y, et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270–80. doi: 10.3748/wjg.v20.i28.9270 .

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy;PLOS ONE;2024-05-23

2. The nucleoside analog 4′-fluorouridine suppresses the replication of multiple enteroviruses by targeting 3D polymerase;Antimicrobial Agents and Chemotherapy;2024-04-30

3. Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study;Journal of Clinical Medicine;2023-05-17

4. Efficacy and Safety of Adding Ribavirin to Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C Infection- a Systematic Review and Meta-Analysis;2023

5. Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C;Journal of Clinical Medicine;2021-08-31